<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B-cell <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL) is the most common human <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Deregulation of the T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo> 1 oncogene (TCL1) in mouse B cells causes a CD5(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> similar to aggressive human CLL </plain></SENT>
<SENT sid="2" pm="."><plain>To examine the mechanisms by which Tcl1 protein exerts its oncogenic activity in B cells, we performed proteomics experiments to identify its interacting partners </plain></SENT>
<SENT sid="3" pm="."><plain>We found that Tcl1 physically interacts with de novo DNA methylthansferases Dnmt3A and Dnmt3B </plain></SENT>
<SENT sid="4" pm="."><plain>We further investigated the effects of Tcl1 up-regulation on the enzymatic activity of Dnmt3A and found that Tcl1 overexpression drastically inhibits Dnmt3A function </plain></SENT>
<SENT sid="5" pm="."><plain>In addition, B cells from TCL1 transgenic mice showed a significant decrease in DNA methylation compared with WT controls </plain></SENT>
<SENT sid="6" pm="."><plain>Similarly, CLL samples with high Tcl1 expression showed a decrease in DNA methylation compared with CLL samples with low Tcl1 expression </plain></SENT>
<SENT sid="7" pm="."><plain>Given the previous reports of inactivating mutations of DNMT3A in <z:hpo ids='HP_0004808'>acute myelogenous leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>, our results suggest that inhibition of de novo DNA methylation may be a common oncogenic mechanism in <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
</text></document>